Related Experiment Video

Updated: Feb 6, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.2K

The role of tivozanib in advanced renal cell carcinoma therapy

Bernard Escudier1, Camillo Porta2, Tim Eisen3

  • 1a Department of Oncological Medicine , Institut Gustave Roussy , Villejuif , France.

Expert Review of Anticancer Therapy
|August 8, 2018
PubMed
Abstract

Insights

Tivozanib, a selective VEGF receptor tyrosine kinase inhibitor (VEGFR-TKI), shows efficacy and improved tolerability for advanced renal cell carcinoma (RCC). Its selectivity may offer better outcomes in combination therapies for metastatic RCC.

Area of Science:

  • Oncology
  • Pharmacology
  • Nephrology

Background:

  • Vascular Endothelial Growth Factor (VEGF)-targeting therapies are recommended for advanced renal cell carcinoma (RCC).
  • Tolerability, including off-target effects, remains a challenge with current treatments.
  • Tivozanib offers selective inhibition of VEGFRs with potentially reduced off-target interactions.

Purpose of the Study:

  • To review the clinical development of tivozanib in advanced RCC.
  • To discuss the efficacy and safety of tivozanib in various treatment settings.
  • To explore the potential of tivozanib in combination therapies.

Main Methods:

  • Review of pivotal Phase III randomized clinical trial comparing tivozanib with sorafenib in VEGF- and mTOR therapy-naïve advanced RCC patients.
  • Inclusion of data from ongoing trials investigating tivozanib in refractory disease and combination therapy with checkpoint inhibitors.

Main Results:

  • Tivozanib demonstrated efficacy with improved tolerability compared to multikinase VEGFR-TKIs in advanced RCC.
  • Ongoing trials are evaluating tivozanib's efficacy and safety in refractory disease and combination with immunotherapy.
  • The selectivity of tivozanib suggests potential for acceptable tolerability in combination therapy.

Conclusions:

  • Tivozanib provides a new first-line treatment option for advanced/metastatic RCC in Europe.
  • Its VEGFR selectivity may enhance tolerability, particularly in combination regimens.
  • Further research is exploring tivozanib's role in refractory disease and combination therapies for advanced RCC.
Keywords:
Renal cell carcinomaTKIVEGFRkidney cancertivozanibtyrosine kinase inhibitor

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.1K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
225
Role of Myosin in Cell Migration01:18

Role of Myosin in Cell Migration

Myosins are multimeric motor proteins involved in various cellular processes such as migration, adhesion, and proliferation. Myosin II is the most common type in animal cells, which binds and cross-links actin filaments.
Myosin II  is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....
3.4K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
480
Role of Microtubules in Cell Wall Deposition01:02

Role of Microtubules in Cell Wall Deposition

Microtubules are small hollow tubes in eukaryotic cells. The cell wall microtubules are polymerized dimers of two globular proteins, α-tubulin and β-tubulin, two globular proteins. With a diameter of about 25 nm, microtubules are the widest components of the cytoskeleton. They help the cell resist compression and provide a track along which vesicles move through the cell or pull replicated chromosomes to opposite ends of a dividing cell. Microtubules go through quick cycles of...
3.1K